A buy-side equity research analyst and a deputy portfolio manager covering global financials.
With nearly 10 years of investment experience on both buy- and sell-side, I provide research coverage on U.S., European, LatAm and CEEMEA banks/financials, including fundamental analysis, DCF/multiples valuation, commentaries on price-sensitive events and actionable trading ideas. If you are interested in the topic, click the "Follow" button beside my name on the top of the page. Thank you for your time.
Just a guy with an interest in the stock market. Trying to find good companies with good yields so I can retire.
I am long:
Energy: CVX COP XOM
Finance: JPM AFL MA V
Retail: TGT VFC
Industrials: BA GE MMM HON CMI
Teleco: T VZ
Consumer goods: MO PM KO PG GIS PEP
Consumer Discretionary: LUV SBUX DIS
Tech: MSFT APPL CSCO QCOM
Health: ABBV JNJ CVS GILD
REITs: O VTR
Preclinical target discovery and validation at a leading biotechnology firm. Primary research interests: neurology and oncology. Investment strategy centered on companies with mid- to late-stage assets and proprietary technology platforms.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
Born in 1958, I am a small investor who has taken his lumps. When I started out, I made a lot of money trading. Then I lost twice as much, when market conditions changed but my methods didn't.
Intellectually I believe that dividend investing is probably the best way to go. However, I am still addicted to searching for a good deal--call it value investing, or swing investing, or what you will.
In the first nine months of 2016, my portfolio is up 126%. Needless to say, I am happy about that. Especially as a part-time investor with a day job. But like everyone else, I would like to do even better.
Chris Cook's background is in UK market regulation, latterly as a Director of the International Petroleum Exchange. In recent years, he has been a strategic market consultant and commentator, and has also been actively developing new partnership-based legal and financial structures or "enterprise models". Since 2011 Chris has been a Senior Research Fellow at the Institute for Security & Resilience Studies at University College London.
Over 5 years' experience on the buyside. Spent nearly 3 years of my professional career as a Research Analyst investing in public markets (stocks) and the other 2 in the private arena (VC/growth equity and distressed/restructurings). I am a highly passionate investor and always consider both the macroeconomic backdrop coupled with in-depth fundamental research to identify the best investment ideas, which are generally contrarian, value-biased, opportunistic or event-driven.
I specialize in understanding the dynamics that underlie and drive investment performance in today's global financial markets, despite a muddling of views among regulators and investors alike in the new, free money era. Following the global financial crisis, expansionary monetary policies of unprecedented magnitude implemented by major central banks across the globe (primarily those of the so called "core economies") have completely redefined the ways in which the global markets operate. I am not your typical hedge fund or money manager who stamps a disclaimer on investment performance with the assertion that "we are bottom-up, fundamental equity investors" who "do not attempt to forecast the markets." I go far beyond this basic, fundamental analysis and offer unique foresight into major anticipated (equity and credit) market movements BEFORE they materialize.
I have a with a knack for identifying under- and over-valued positions and a strong understanding of macroeconomics. I constantly analyze and evaluate central bank policies globally as well as global trade conditions. I have unique experience particular to sectors such as energy (both conventional and non-conventional), agriculture, infrastructure and real assets (industrials, real estate, water infrastructure, roads/railways, etc.), in addition to chemicals and consumer products; however, I've been a generalist research analyst for the majority of my career to date. Options are a trading mechanism of choice, particularly when I have visible catalysts for near-term price appreciation (or depreciation in the case of puts). I also utilize options strategies to earn large profits with limited downside risk.
Williams Equity Research analyzes trading strategy, individual stocks, asset classes, market sectors, and risk to reward parameters in order to provide valuable insight to the Seeking Alpha community.
The author has over 10 years of experience in the financial markets working in areas of equities trading, complex product analysis, and risk management, as well as a graduate level education in the areas of petroleum engineering (full), law (partial), and finance (MBA, partial).
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
Ken McGaha has been managing his own investment portfolios for over 20 years. On July 20, 2012 he launched the Self-Made Millionaire Tracking Portfolio with a portion of his capital as an aid to teach younger members of his extended family how he built his own investment portfolios and maintains them today.
Ken's flagship Self-Made Millionaire Tracking Portfolio had delivered a 18.57% annualized rate of return on capital as of May 16, 2015 against its benchmark objective of 15% annualized.
Self-Made Millionaire was closed to the public in December of 2015 to allow Ken to focus on private analysis work. He is now engaged in independent analysis of private and public companies for individual clients.
Two guys who love Investing, Dividends, Frugality, Passive Income & attempting to Reinvest Our Dividends to one day achieve Financial Freedom! Follow us on your journey towards a work-free life!
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
Founder, CEO and managing director of Vailshire Capital Management, LLC, in Colorado Springs.
Managing director of Vailshire Partners, LP: a multi-strategy "two-pronged" hedge fund seeking present value, future growth, and current income through an active safe options strategy. The fund frequently sells covered calls and naked puts to earn generous income and profit from market volatility. As a physician, a strong emphasis is placed on health care, pharmaceutical and biotech equities.
Retired on June 30, 2015 from practicing medicine as a Diagnostic and Interventional Radiologist in Colorado Springs, CO.
Currently a full-time investment professional, managing Vailshire Partners, 30+ separately managed accounts via Vailshire Capital Management, as well as, working as an "emerging manager" for a fund-of-funds based in New York.
I am a Ph.D. level scientist at a major pharmaceutical company. Previously I was an NIH Cancer Postdoctoral fellow at UPENN. Through my extensive research background, I am able to quickly decipher clinical information and act on it. I specialize in analyzing and trading biotech/healthcare stocks both long and short. I maintain a few core positions and trade clinical events based on extensive research to realize large percentage gains. I am open to opportunities in consulting for financial firms or local advisors. Please contact me if you are interested.
Disclosure: I'm not a financial adviser. All articles are my opinion - they are not suggestions to buy or sell any securities. Perform your own due diligence and consult a financial professional before trading.
Michael T. Snyder is a graduate of the McIntire School of Commerce at the University of Virginia and has two law degrees from the University of Florida. He is an attorney that has worked for some of the largest and most prominent law firms in Washington D.C. and who now resides outside of Seattle, Washington. He is a very active blogger and is also a respected researcher, writer, speaker and activist. You can follow him on The Economic Collapse blog: http://theeconomiccollapseblog.com/
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Most people follow the path of least resistance making poor dietary and health choices. People also spend their discretionary income and credit on retail, shiny computer gadgets, smartphones, and cable TV instead of on retirement savings. One can profit from this behavior by buying stock in companies that support other people's bad decisions.
I focus on investing long-term in high-quality, dividend-paying companies that tap into poor lifestyle choices across the economic spectrum.
I'm long on companies like Coca-Cola (sugar water), Kraft, and Mondelez (pre-packaged junk food), Altria and Philip Morris, Int (smokers), Abbott and AbbVie (drugs and equipment to treat poor lifestyle choices), Intel (computer chips to support shiny gadgets & now mobile phones too), Disney and Comcast for entertainment, internet and cable, and of course who can forget booze (Diageo) and lattes (Starbucks).
And since most people don't have a lot of money saved, one can profit from stores that sell cheap clothing (TJX Companies), banks to lend them money (Wells Fargo), and energy to move them about and heat their homes (Williams Companies and Chevron).
My complete portfolio currently consists of the following stocks:
AbbVie Inc (ABBV)
Abbott Laboratories (ABT)
Chevron Corporation (CVX)
Diageo Plc (DEO)
Emerson Electric Co (EMR)
Gramercy Properties Trust (GPT)
The Home Depot (HD)
Intel Corporation (INTC)
The Coca-Cola Company (KO)
The Kraft Heinz Company (KHC)
McCormick & Company (MKC)
Mondelez International Inc (MDLZ)
Altria Group Inc (MO)
Norfolk Southern Company (NSC)
Proctor & Gamble (PG)
The TJX Companies, Inc. (TJX)
Union Pacific Corporation (UNP)
The Walt Disney Company (DIS)
Wells Fargo & Co (WFC)
Williams Companies (WMB)
Jessica Rabe is a research associate at ConvergEx Group. She graduated from Gordon College with a B.A. in economics, where she founded the Global Perspectives column in the Gordon College newspaper. Jessica also writes for The American Enterprise Institute's Values and Capitalism blog, and has contributed articles to The Center for Public Justice's online journal, Shared Justice.
Jessica was previously a research analyst at Right Blend Investing LLC, a Registered Investment Advisor in Hillsborough, New Jersey. She has interned at EMC Brazil’s Big Data Research and Development Center in Rio de Janeiro, Brazil, and for U.S. Congressman Rodney Frelinghuysen.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.